enGene Holdings Inc. has recently released its 10-Q report, providing a detailed insight into the company's financial condition and results of operations. The company, through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology firm based in Montreal, Canada. enGene is primarily focused on developing genetic medicines to address diseases with high clinical needs, starting with non-muscle invasive bladder cancer (NMIBC). Its lead product candidate is detalimogene voraplasmid, a therapy designed to promote a pro-inflammatory, anti-tumor microenvironment throughout the bladder urothelium.
In the 10-Q report, enGene Holdings Inc. disclosed that it has not generated any revenue from product sales and has incurred net losses since its inception. For the three months ended January 31, 2026, the company reported a net loss of $29.8 million, compared to $24.6 million for the same period in 2025. As of January 31, 2026, enGene had an accumulated deficit of $401.8 million and cash, cash equivalents, and marketable securities of $312.5 million.
The report also highlighted the company's ongoing Phase 1/2 open-label trial, referred to as "LEGEND," which is studying detalimogene in patients with high-risk BCG-unresponsive NMIBC with CIS with or without concomitant papillary disease. The Phase 2 portion of LEGEND is comprised of three cohorts, and enGene is also exploring the clinical application of detalimogene to various additional NMIBC patient populations.
Furthermore, enGene revealed that it expects to continue incurring significant expenses and increasing operating losses for the foreseeable future as it advances the ongoing LEGEND study of detalimogene and pursues potential pipeline expansion via additional detalimogene development opportunities and other compounds. The company anticipates the need for substantial additional funding to support its continuing operations and growth strategy.
The 10-Q report also provided insights into enGene's research and development expenses, which account for a significant portion of its operating expenses. These expenses primarily consist of costs incurred for research activities, including drug discovery efforts and the development of product candidates. The company recognizes direct development costs based on an evaluation of the progress to completion of specific tasks and expects its research and development expenses to continue increasing as it progresses its ongoing clinical trial for detalimogene and discovers and develops additional product candidates.
Following these announcements, the company's shares moved 0.98%, and are now trading at a price of $9.31. Check out the company's full 10-Q submission here.
